Pharmacotherapy of neuroblastoma

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 9, 2010, Pages 1467-1478

  George, Rani E ^a,b   Diller, Lisa ^a,b   Bernstein, Mark L ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c IWK HEALTH CENTRE   (Canada)

Author keywords

ALK tyrosine kinase; Anti angiogenic agents; Apoptosis inducers; Epigenetic modifiers; Heat shock proteins; High risk neuroblastoma; Immunotherapy; MIBG; Retinoids; Targeted therapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; 5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IMC A 12; IRINOTECAN; ISOTRETINOIN; LESTAURTINIB; MELPHALAN; OBATOCLAX; OBLIMERSEN; PLATINUM DERIVATIVE; SUNITINIB; TANESPIMYCIN; TEMSIROLIMUS; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VINCRISTINE; VORINOSTAT;

ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW SUPPRESSION; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; GENETIC EPIGENESIS; HUMAN; INFECTION; LIVER TOXICITY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; NONHUMAN; PROGNOSIS; PROTEIN TARGETING; RADIOSENSITIZATION; REVIEW;

ANTINEOPLASTIC AGENTS; APOPTOSIS; EPIGENESIS, GENETIC; HUMANS; IMMUNOTHERAPY; INFANT; NEUROBLASTOMA; PROGNOSIS;

EID: 77952709335     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.482100     Document Type: Review

References (118)

1. Available from: http://seer.cancer.gov/ publications/childhood/ sympathetic.pdf. National Cancer Institute. Surveillance, Epidemiology and End Results Database. 2005
2. Woods WG, Gao RN, Shuster JJ, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med 2002;346(14):1041-1046
3. Mueller S, Matthay KK. Neuroblastoma: biology and staging. Curr Oncol Rep 2009;11(6):431-438
4. Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am 2008;55(1):97-120, x
5. George RE, London WB, Cohn SL, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 2005;23(27):6466-6473
6. Schmidt ML, Lal A, Seeger RC, et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 2005;23(27):6474-6480
7. London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005;23(27):6459-6465
8. Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009;27(2):298-303
9. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009;27(2):289-297
10. Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 1994;12(12):2607-2613
11. Valteau-Couanet D, Michon J, Boneu A, et al. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J Clin Oncol 2005;23(3):532-540
12. Available from: https://members. childrensoncologygroup.org/Prot/A3973/ A3973-Fall07FINAL.pdf. A3973, Final study progress report. 2007
13. Zamboni WC, Stewart CF, Thompson J, et al. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. J Natl Cancer Inst 1998;90(7):505-511
14. Nitschke R, Parkhurst J, Sullivan J, et al. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol-Oncol 1998;20(4):315-318
15. Saylors RL III, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001;19(15):3463-3469 (Pubitemid 32730082)
16. Frantz CN, London WB, Diller L, et al. Recurrent neuroblastoma: Randomized treatment with topotecan + cyclophosphamide (T + C) vs topotecan alone(T). A POG/CCG Intergroup Study. ASCO Annual Meeting Proceedings 2004. J Clin Oncol 2004;22(14S):8512
17. Tubergen DG, Stewart CF, Pratt CB, et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a Pediatric Oncology Group study. J Pediatr Hematol-Oncol 1996;18(4):352-361
18. Kushner BH, Kramer K, Meyers PA, et al. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. Med Pediatr Oncol 2000;35(5):468-474
19. Park JR, Stewart CF, London WB, et al. A topotecan-containing induction regimen for treatment of high risk neuroblastoma. ASCO Annual Meeting Proceedings Part I 2006. J Clin Oncol 2006;24(18S):9013
20. Wagner LM, Danks MK. New therapeutic targets for the treatment of high-risk neuroblastoma. J Cell Biochem 2009;107(1):46-57
21. Fong A, Park JR. High-risk neuroblastoma: a therapy in evolution. Pediatr Hematol Oncol 2009;26(8):539-548
22. Taggart D, Dubois S, Matthay KK. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging 2008;52(4):403-418
23. Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131- metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 2007;25(9):1054-1060
24. Matthay KK, Tan JC, Villablanca JG, et al. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 2006;24(3):500-506
25. Schmidt M, Simon T, Hero B, et al. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin 2006;45(4):145-151, quiz N39-40
26. Vaidyanathan G. Meta-iodobenzylguanidine and analogues: chemistry and biology. Q J Nucl Med Mol Imaging 2008;52(4):351-368
27. Schulz G, Cheresh DA, Varki NM, et al. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 1984;44(12 Pt 1):5914-5920
28. Kramer K, Gerald WL, Kushner BH, et al. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma. Med pediatr oncol 2001;36(1):194-196
29. Modak S, Cheung NK. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest 2007;25(1):67-77
30. Cheung NK, Kushner BH, Cheung IY, et al. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 1998;16(9):3053-3060
31. Kushner BH, Kramer K, Cheung NK. Phase II tiral of the anti-GD2 monoclonal antibody 3F8 and granulocyte-macrophage colonystimulating factor for neuroblastoma. J Clin Oncol 2001;19:4189-4194
32. Statement from the Children's Oncology Group regarding recently released early results of a clinical trial for children with high-risk neuroblastoma. 2009. Available from: http://www.curesearch.org/. [Cited]
33. Yu AL, Gilman A, Ozkaynak MF, et al. A phase III randomized trial of the chimeric anti-GD2antibody ch14.18 with GM-CSF and IL2 as immunotherapy following dose intensive chemotherapy for high-risk neuroblastoma: Children's Oncology Group (COG) study ANBL0032 [abstract]. J Clin Oncol 2009;27(Suppl 15):A-10067z
34. Hank JA, Surfus J, Gan J, et al. Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother 1994;15(1):29-37
35. Handgretinger R, Anderson K, Lang P, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 1995;31A:261-267
36. Gilman AL, Ozkaynak MF, Matthay KK, et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J Clin Oncol 2009;27(1):85-91
37. Simon T, Hero B, Faldum A, et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 2004;22(17):3549-3557
38. Osenga KL, Hank JA, Albertini MR, et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res 2006;12(6):1750-1759
39. Shusterman S, London WB, Gillies SD, et al. Anti-neuroblastoma activity of hu14.18-IL2 against minimal residual disease in a Children's Oncology Group phase II study. J Clin Oncol 2008;26(15S):abstract 3002.
40. Park JR, Digiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007;15(4):825-833
41. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14(11):1264-1270
42. Reynolds CP, Kane DJ, Einhorn PA, et al. Response of neuroblastoma to retinoic acid in vitro and in vivo. Prog Clin Biol Res 1991;366:203-211
43. Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ. Retinoid therapy of high-risk neuroblastoma. Cancer Lett 2003;197(1-2):185-192
44. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341(16):1165-1173
45. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol 2009;27(7):1007-1013
46. Mariotti A, Marcora E, Bunone G, et al. N-(4-hydroxyphenyl)retinamide: a potent inducer of apoptosis in human neuroblastoma cells. J Natl Cancer Inst 1994;86(16):1245-1247
47. Reynolds CP, Wang Y, Melton LJ, et al. Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide. Med Pediatr Oncol 2000;35(6):597-602
48. Maurer BJ, Metelitsa LS, Seeger RC, et al. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines [see comments]. J Natl Cancer Inst 1999;91(13):1138- 1146
49. Villablanca JG, Krailo MD, Ames MM, et al. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol 2006;24(21):3423-3430
50. Rossler J, Taylor M, Geoerger B, et al. Angiogenesis as a target in neuroblastoma. Eur J Cancer 2008;44(12):1645-1656
51. Shusterman S, Maris JM. Prospects for therapeutic inhibition of neuroblastoma angiogenesis. Cancer Lett 2005;228(1-2):171-179
52. Jakovljevic G, Culic S, Stepan J, et al. Vascular endothelial growth factor in children with neuroblastoma: a retrospective analysis. J Exp Clin Cancer Res 2009;28:143
53. Ozer E, Altungoz O, Unlu M, et al. Association of MYCN amplification and 1p deletion in neuroblastomas with high tumor vascularity. Appl Immunohistochem Mol Morphol 2007;15(2):181-186
54. Kang J, Rychahou PG, Ishola TA, et al. N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma. Oncogene 2008;27(28):3999-4007
55. Segerstrom L, Fuchs D, Backman U, et al. The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. Pediatr Res 2006;60(5):576-581
56. Sims TL, Williams RF, Ng CY, et al. Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease. Surgery 2008;144(2):269-275
57. Zaghloul N, Hernandez SL, Bae JO, et al. Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma. Int J Oncol 2009;34(2):401-407
58. Svensson A, Backman U, Fuchs D, et al. Angiogenesis can be reduced without significant reduction of tumor growth. Anticancer Res 2007;27(6B):3883-3889
59. Dickson PV, Hamner JB, Sims TL, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007;13(13):3942-3950
60. Backman U, Svensson A, Christofferson RH, Azarbayjani F. The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis. Anticancer Res 2008;28(3A):1551-1557
61. Russell H, Declerck Y, Ara T, et al. A phase I study of zoledronic acid and low-dose cyclophosphamide in children with recurrent/refractory neuroblastoma: A New Approaches to Neuroblastoma Therapy study. J Clin Oncol 2009;27(15s):abstract 10022
62. Opel D, Poremba C, Simon T, et al. Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res 2007;67(2):735-745
63. Jaboin J, Kim CJ, Kaplan DR, Thiele CJ. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3¢-kinase pathway. Cancer Res 2002 62(22):6756-6763
64. Ho R, Eggert A, Hishiki T, et al. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 2002;62(22):6462-6466
65. Kurmasheva RT, Harwood FC, Houghton PJ. Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors. Mol Cancer Ther 2007;6(5):1620-1628
66. Coulter DW, Blatt J, D'Ercole AJ, Moats-Staats BM. IGF-I receptor inhibition combined with rapamycin or temsirolimus inhibits neuroblastoma cell growth. Anticancer Res 2008;28(3A):1509-1516
67. Marimpietri D, Brignole C, Nico B, et al. Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis. Clin Cancer Res 2007;13(13):3977-3988
68. Spunt SL, Grupp S, Vik T, et al. Phase I safety, pharmacokinetic and exploratory biomarker study of intravenous temsirolimus in children with advanced solid tumors. Proc Am Soc Pediatr Hematol/Oncol, Cincinnati, OH; 2008
69. Dancey JE, Curiel R, Purvis J. Evaluating temsirolimus activity in multiple tumors: a review of clinical trials. Semin Oncol 2009;36(Suppl 3):S46-58
70. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993;328(12):847-854
71. Evans AE, Kisselbach KD, Liu X, et al. Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB. Med Pediatr Oncology 2001;36(1):181-184
72. Evans AE, Kisselbach KD, Yamashiro DJ, et al. Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts. Clin Cancer Res 1999;5(11):3594-3602
73. George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008;455(7215):975-978
74. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455(7215):971-974
75. Janoueix-Lerosey I, Lequin D, Brugieres L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455(7215):967-970
76. Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455(7215):883-884
77. Osajima-Hakomori Y, Miyake I, Ohira M, et al. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol 2005;167(1):213-222
78. George RE, Attiyeh EF, Li S, et al. Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS ONE 2007;2(2):e255
79. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007;6(12 Pt 1):3314-3322
80. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67(9):4408-4417
81. El-Badry OM, Romanus JA, Helman LJ, et al. Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II. J Clin Invest 1989;84(3):829-839
82. Liu X, Turbyville T, Fritz A, Whitesell L. Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice. Cancer Res 1998;58(23):5432-5438
83. Misawa A, Hosoi H, Arimoto A, et al. N-Myc induction stimulated by insulin-like growth factor I through mitogen-activated protein kinase signaling pathway in human neuroblastoma cells. Cancer Res 2000;60(1):64-69
84. Geoerger B, Daudigeous E, Debussche LRJ, et al. The anti insulin-like growth factor 1 receptor (IGF1-R) antibody AVE1642 exhibits anti-tumor activity against neuroblastoma cell lines and xenografts [abstract 1222]. Proc Am Assoc Cancer Res 2006;47:289
85. Dole M, Nunez G, Merchant AK, et al. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 1994;54(12):3253-3259
86. Castle VP, Heidelberger KP, Bromberg J, et al. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am J pathol 1993;143(6):1543-1550
87. Mejia MC, Navarro S, Pellin A, et al. Study of bcl-2 protein expression and the apoptosis phenomenon in neuroblastoma. Anticancer Res 1998;18(2A):801-806
88. Reed JC, Stein C, Subasinghe C, et al. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res 1990;50(20):6565-6570
89. Reed JC, Meister L, Tanaka S, et al. Differential expression of Bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res 1991;51(24):6529-6538
90. Rheingold SR, Hogarty MD, Blaney SM, et al. Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study. J Clin Oncol 2007;25(12):1512-1518
91. Teitz T, Wei T, Valentine MB, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000;6:529-535
92. Fujita T, Igarashi J, Okawa ER, et al. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst 2008;100(13):940-949
93. George RE, Medeiros-Nancarrow C, Adamson PC, et al. A Phase I study of decitabine (DCT) in combination with doxorubicin (DOX) and cyclophosphamide (CTX) in the treatment of relapsed or refractory solid tumors-a Children's Oncology Group Study. J Clin Oncol 2005;23(No.16S):abstract 8530
94. George R, Lahti J, Ingle M, et al. Decitabine (DAC) in combination with doxorubicin (DOX) and cyclophosphamide (CTX) in relapsed neuroblastoma (NBL): a Children's Oncology Group Study. J Clin Oncol 2007;25:18S:abstract 9565
95. Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21(1):103-107
96. Zhu WG, Lakshmanan RR, Beal MD, Otterson GA. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 2001;61(4):1327-1333
97. Glick RD, Swendeman SL, Coffey DC, et al. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res 1999;59(17):4392-4399
98. Coffey DC, Kutko MC, Glick RD, et al. Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med Pediatr Oncol 2000;35(6):577-581
99. Coffey DC, Kutko MC, Glick RD, et al. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res 2001;61(9):3591-3594
100. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001;1(3):181-193
101. Fouladi M, Park, JR, Sun J, et al. A phase I trial and pharmacokinetic study of vorinostat (SAHA) in combination with 13 cis-retinoic acid in children with refractory neuroblastomas, medulloblastomas, primitive neuroectodermal tumors (PNETs), and atypical teratoid rhabdoid tumor. J Clin Oncol 2008;26:10012
102. Cusack JC Jr, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001;61(9):3535-3540
103. Brignole C, Marimpietri D, Pastorino F, et al. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst 2006;98(16):1142-1157
104. Khan T, Stauffer JK, Williams R, et al. Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors. J Immunol 2006;176(10):6302-6312
105. Blaney SM, Bernstein M, Neville K, et al. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol 2004;22(23):4804-4809
106. Maris JM, Morton CL, Gorlick R, et al. Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010. [Epub ahead of print]
107. Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2001;2(1):21-32
108. Sen S, Zhou H, Zhang RD, et al. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 2002;94(17):1320-1329
109. Bischoff JR, Anderson L, Zhu Y, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998;17(11):3052-3065
110. Otto T, Horn S, Brockmann M, et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009;15(1):67-78
111. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 2003;22(4):451-464
112. Hirota T, Kunitoku N, Sasayama T, et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003;114(5):585-598
113. Whitesell L, Mimnaugh EG, De Costa B, et al. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994;91(18):8324-8328
114. Bagatell R, Beliakoff J, David CL, et al. Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. Int J Cancer 2005;113(2):179-188
115. Kang J, Kamal A, Burrows FJ, et al. Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors. Anticancer Res 2006;26(3A):1903-1908
116. Bagatell R, Gore L, Egorin MJ, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res 2007;13(6):1783-1788
117. Weigel BJ, Blaney SM, Reid JM, et al. A phase I study of 17-allylaminogeldanamycin in relapsed/ refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin Cancer Res 2007;13(6):1789-1793
118. Jacobson LO SC, Barron Guzman ES, Smith T, et al. Ntirogen mustard therapy. JAMA 1946;132:263-271